SCHEMBL850429

SCHEMBL850429

O=C(O)c1ccc(C(F)(F)F)c(F)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 5/20 0.57
LMNA P02545 2/20 0.50
MAPK1 P28482 1/20 0.50
HTT P42858 1/20 0.50
RAB9A P51151 1/20 0.50
TTR P02766 1/20 0.50
KCNQ3 O43525 1/20 0.48
KCNQ2 O43526 1/20 0.48
KCNE1 P15382 1/20 0.48
KCNQ1 P51787 1/20 0.48
RXRA P19793 1/20 0.46
RXRB P28702 1/20 0.46
RXRG P48443 1/20 0.46
SRD5A2 P31213 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.42
RORC P51449 1/20 0.42
TP53 P04637 1/20 0.42
TSHR P16473 1/20 0.42
RARA P10276 1/20 0.42
RARB P10826 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29620952 1.00 KIF11 (0.57) KIF11LMNAMAPK1HTTRAB9A
Hydrochloric Acid SCHEMBL31439018 0.98 KIF11 (0.56) KIF11LMNAMAPK1HTTRAB9A
SCHEMBL418896 0.86 LMNA (0.49) KIF11LMNAMAPK1HTTRAB9A
SCHEMBL16104820 0.85 LMNA (0.51) KIF11LMNAMAPK1HTTRAB9A
SCHEMBL5360083 0.85 LMNA (0.47) KIF11LMNAMAPK1HTTRAB9A
SCHEMBL31438988 0.84 TAS1R3 (0.54) KIF11LMNAMAPK1HTTRAB9A
SCHEMBL78878 0.84 TAS1R3 (0.54) KIF11LMNAMAPK1HTTRAB9A
SCHEMBL827082 0.83 RXRA (0.48) KIF11TTRRXRARXRBRXRG
SCHEMBL31319449 0.83 RXRA (0.48) KIF11TTRRXRARXRBRXRG
SCHEMBL313169 0.82 KIF11 (0.75) KIF11KCNQ3KCNQ2KCNE1KCNQ1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 259 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119431706-A Fatigue-resistant polyurethane elastomer and preparation method and application thereof 万勋科技(深圳)有限公司 2025-02-14 CN claimed
CN-118184679-A Photothermal agent and preparation method thereof, photothermal nanoparticle and preparation method thereof, insulating material and self-repairing method of insulating material 中国石油天然气股份有限公司 2024-06-14 CN claimed
EP-3551633-B1 SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS LEO PHARMA AS (DK) 2021-03-31 EP claimed
CN-107681052-B Main group metal complexes as p-dopants for organic electronic matrix materials 西门子公司 2020-03-24 CN claimed
CN-110088108-A SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS 利奥制药有限公司 2019-08-02 CN claimed
US-8853619-B2 Method for detecting tracer compounds for hydrocarbon production TOTAL S.A. (FR) 2014-10-07 US claimed
US-20110260051-A1 METHOD FOR DETECTING TRACER COMPOUNDS FOR HYDROCARBON PRODUCTION TOTAL S.A. (FR) 2011-10-27 US claimed
US-20260001870-A1 INHIBITOR COMPOUNDS Cincera Therapeutics Pty Ltd (AU) 2026-01-01 US disclosed
US-20250368647-A1 NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS GLAXOSMITHKLINE IP DEV LTD (GB) 2025-12-04 US disclosed
US-12448371-B2 Inhibitor compounds Cincera Therapeutics Pty Ltd (AU) 2025-10-21 US disclosed
CN-115974872-B Azacyclic derivatives, pharmaceutical compositions thereof and uses thereof 南方科技大学 2025-05-02 CN disclosed
US-20250129067-A1 PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF PROGENTOS THERAPEUTICS, INC. (US) 2025-04-24 US disclosed
CN-119431706-A Fatigue-resistant polyurethane elastomer and preparation method and application thereof 万勋科技(深圳)有限公司 2025-02-14 CN disclosed
EP-1185869-A2 LIGAND-ANCHOR CONJUGATES FOR PRODUCING A BIOSENSOR LAYER Graffinity Pharmaceutical Design GmbH (DE) 2002-03-13 EP disclosed
CN-1334812-A Piperazine derivatives FUJISAWA PHARMACEUTICAL CO (JP) 2002-02-06 CN disclosed
EP-1140924-A1 PIPERAZINE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-10-10 EP disclosed
EP-1091958-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2001-04-18 EP disclosed
WO-2000073796-A2 LIGAND-ANCHOR CONJUGATES FOR PRODUCING A BIOSENSOR LAYER GRAFFINITY PHARMACEUTICAL DESIGN GMBH (DE) 2000-12-07 WO disclosed
WO-2000035915-A1 PIPERAZINE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-06-22 WO disclosed
WO-2000001692-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2000-01-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250368647-A1 NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS SCN8A, SCN2A, SCN5A KIF11 2994/4885LMNA 634/4885MAPK1 1311/4885
US-20260001870-A1 INHIBITOR COMPOUNDS CES1, NCEH1, NR1H2 KIF11 3494/4885LMNA 277/4885MAPK1 1857/4885
US-12448371-B2 Inhibitor compounds SERPINB1, MMP1, SSB KIF11 4192/4885LMNA 765/4885MAPK1 567/4885
US-20250129067-A1 PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF PDGFRB, PDGFRA, PDGFA KIF11 2769/4885LMNA 3890/4885MAPK1 1249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.